Home  |  Contact

Cellosaurus BV-173 (CVCL_0181)

[Text version]

Cell line name BV-173
Synonyms BV173
Accession CVCL_0181
Resource Identification Initiative To cite this cell line use: BV-173 (RRID:CVCL_0181)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: 30-35 hours (PubMed=6572735); ~48 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Disease Chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C3174)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_5K95 (BV-173/E255K)
Sex of cell Male
Age at sampling 45Y
Category Cancer cell line
STR profile Source(s): CLS; Cosmic-CLP; DSMZ

Penta D11
Penta E12,16

Run an STR similarity search on this cell line

Pegoraro L., Matera L., Ritz J., Levis A., Palumbo A., Biagini G.
Establishment of a Ph1-positive human cell line (BV173).
J. Natl. Cancer Inst. 70:447-453(1983)

PubMed=3856862; DOI=10.1073/pnas.82.6.1810
Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.
Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985)

PubMed=3098690; DOI=10.1002/ijc.2910390116
Th'ng K.H., Garewal G., Kearney L., Rassool F., Melo J.V., White H., Catovsky D., Foroni L., Luzzatto L., Goldman J.M.
Establishment and characterization of three new malignant lymphoid cell lines.
Int. J. Cancer 39:89-93(1987)

PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9
Keating A.
Ph positive CML cell lines.
Baillieres Clin. Haematol. 1:1021-1029(1987)

PubMed=1720549; DOI=10.1073/pnas.88.23.10735
Ziemin-van der Poel S., McCabe N.R., Gill H.J., Espinosa R. III, Patel Y., Harden A., Rubinelli P., Smith S.D., Le Beau M.M., Rowley J.D., Diaz M.O.
Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.
Proc. Natl. Acad. Sci. U.S.A. 88:10735-10739(1991)

PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2
Matsuo Y., Drexler H.G.
Establishment and characterization of human B cell precursor-leukemia cell lines.
Leuk. Res. 22:567-579(1998)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)

PubMed=16523483; DOI=10.1002/gcc.20317
Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H., Dexter T., Ashworth A., Kearney L.
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Genes Chromosomes Cancer 45:554-564(2006)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cell line collections CLS; 300133/p1775_BV-173
ICLC; HTL99018
Cell line databases/resources CLDB; cl510
CLDB; cl4968
Cell_Model_Passport; SIDM00962
Cosmic-CLP; 910710
GDSC; 910710
IGRhCellID; BV173
Lonza; 117
Ontologies BTO; BTO:0004950
CLO; CLO_0002052
EFO; EFO_0002118
MCCL; MCC:0000072
Biological sample resources BioSample; SAMN03473373
Chemistry resources ChEMBL-Cells; CHEMBL3308228
ChEMBL-Targets; CHEMBL2366145
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM236779
GEO; GSM236815
GEO; GSM886895
GEO; GSM887960
GEO; GSM1374414
GEO; GSM1669633
Other Wikidata; Q54798653
Polymorphism and mutation databases Cosmic; 798672
Cosmic; 910710
Cosmic; 922164
Cosmic; 994184
Cosmic; 996292
Cosmic; 998702
Cosmic; 999741
Cosmic; 1019833
Cosmic; 1026570
Cosmic; 1037734
Cosmic; 1070701
Cosmic; 1071881
Cosmic; 1127249
Cosmic; 1176600
Cosmic; 1191703
Cosmic; 1524792